Company Fundamentals\Company Profile
A Wright Investors' Service Research Report:
Methylgene Incorporated
440 Wheelers Farms Road
Milford, CT 06461 U.S.A.
COMPANY PROFILE
Figures in Canadian Dollars
Wright Quality Rating:LCNN Key Data
MethylGene Inc. (MethylGene) is a Canada-based biopharmaceutical company Ticker:
focused on the discovery, development and commercialization of therapeutics for MYG
cancer. The Company focuses on enzyme inhibitors, specifically for kinases and
histone deacetylases (HDAC). MGCD265 is an orally administered, multi-targeted 2010 Sales:
kinase inhibitor that primarily targets Met, the three VEGFs, Tie-2 and RON receptor
2,389,000
tyrosine kinases. Other compounds or funded programs within the Company during
the year ended December 31, 2009, included: MG516, second generation kinase
inhibitors for cancer; kinase inhibitors for ocular diseases; MG96077, a beta- Major Industry:
lactamase program for antibiotic resistance, and EVP-0334, a potential cognition Drugs, Cosmetics & Health
enhancing agent discovered using MethylGene's HDAC platform, is in Phase I trials Care
sponsored by EnVivo Pharmaceuticals Inc. The Company's product candidates,
clinical candidates, lead compounds and inhibitors target the active sites of Sub Industry:
enzymes. Ethical Drug Manufacturers
Stock Chart Officers
Chairman Country:
Dr. Martin Godbout Canada
President & Chief Executive Currency:
Charles Grubsztajn
Canadian Dollars
Vice President Finance &
Fiscal Year Ends:
Chief Financial Officer
Klaus B. Kepper December
Employees
27
Exchanges:
TOR
Share Type: